Evidence map›Paper›PMID 41044547›Full record

ArticleRespiratory research2025

GLUT and FAPα as molecular markers for interstitial lung disease in systemic sclerosis.

Bo Broens, Conny J van der Laken, Teodora Radonic, Esther J Nossent, Xue D Manz, Douwe J Mulder, Yehya Al-Adwi, C Tji Gan, Wim Timens, Alexandre E Voskuyl and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bo BroensDepartment of Rheumatology and Clinical Immunology, Amsterdam UMC, Amsterdam, the Netherlands.
Conny J van der LakenDepartment of Rheumatology and Clinical Immunology, Amsterdam UMC, Amsterdam, the Netherlands.
Teodora RadonicDepartment of Pathology, Amsterdam UMC, Amsterdam, the Netherlands.
Esther J NossentDepartment of Pulmonary Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
Xue D ManzDepartment of Pulmonary Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
Douwe J MulderDivision of Vascular Medicine, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Yehya Al-AdwiDivision of Vascular Medicine, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
C Tji GanDepartment of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Wim TimensDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Alexandre E VoskuylDepartment of Rheumatology and Clinical Immunology, Amsterdam UMC, Amsterdam, the Netherlands.
Jan Willem DuitmanDepartment of Pulmonary Medicine, Amsterdam UMC, Amsterdam, the Netherlands. j.w.duitman@amsterdamumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical management of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is challenging due to its heterogeneous progression. While recent studies have shown that pulmonary uptake of 18F-FDG and 68Ga-FAPI on positron emission tomography (PET) may indicate ILD activity, the spatial distribution of their molecular targets—GLUT1, GLUT3, and FAPα—in SSc-ILD lung tissue is largely unexplored. Here, we investigate the expression patterns of these markers across varying fibrosis stages in lung tissue of SSc-ILD patients and controls to improve PET interpretation.

methodsImmunohistochemistry for GLUT1, GLUT3, and FAPα was performed on lung tissue from SSc-ILD patients (n = 9) and controls (n = 8). Fibrosis stage and cell-type-specific expression of these markers were analyzed by 2 experienced ILD pathologists, and quantitative staining was assessed using QuPath software. Marker expression was analyzed in and compared between areas with varying fibrosis stages.

resultsGLUT1 positive cells were primarily erythrocytes, GLUT3 positive cells were mainly myeloid cells and FAPα positive cells were predominantly fibroblasts, endothelial cells, epithelial cells, and macrophages. All cells positive for these markers were more present in SSc-ILD compared to controls, with GLUT1 and FAPα positive cells showing highest prevalence in areas with early signs of fibrosis.

conclusionsThe prevalence of cells expressing GLUT1 and FAPα is increased in areas with early signs of fibrosis and the expression of GLUT1, GLUT3 and FAPα is observed in different cell types suggesting that 18F-FDG and 68Ga-FAPI PET each may be useful to visualize different aspects of ILD activity.

Indexed as

GelatinasesGlucose Transporter Type 1Glucose Transporter Type 3Lung Diseases, InterstitialMembrane ProteinsScleroderma, SystemicSerine EndopeptidasesAdultAgedBiomarkersEndopeptidasesFemaleFibroblast Activation Protein AlphaHumansMaleMiddle AgedBiomarkersEndopeptidasesFibroblast Activation Protein AlphaGelatinasesGlucose Transporter Type 1Glucose Transporter Type 3Membrane ProteinsSerine EndopeptidasesSLC2A1 protein, humanSLC2A3 protein, humanFibroblast activation protein alphaGlucose transportersImmunohistochemistryInterstitial lung diseaseSystemic sclerosis

Identifiers

PMID41044547
PMCPMC12495829

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.